Assessing the Rate and Quality of Breast Cancer Treatment Following Initial Diagnosis
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Only 35.4% of early-stage breast cancer patients received guideline-concordant care (GCC), with significant disparities by stage and race. This highlights barriers to standard breast cancer treatment.
Area Of Science
- Oncology
- Health Services Research
Background
- Adherence to breast cancer care guidelines varies in real-world settings.
- Institutional factors can limit guideline-concordant care (GCC).
Purpose Of The Study
- To examine rates of GCC for early-stage breast cancer.
- To evaluate GCC by patient demographics, stage, and during the COVID-19 pandemic.
Main Methods
- Retrospective review of 1455 patients with AJCC Stage 0-III breast cancer (2019-2024).
- GCC defined by NCCN guidelines.
- Analysis of GCC rates by stage, race, insurance, and pandemic timeframe.
Main Results
- 35.4% of patients received GCC; Stage II had lowest rates (28.7%).
- Black patients had highest GCC (52.1%), Asian/Pacific Islander lowest (21.9%).
- GCC rates stable during COVID-19 pandemic, though diagnoses declined.
Conclusions
- Less than half of breast cancer patients met GCC criteria.
- Stage and race disparities indicate institutional and patient-level barriers.
- Improved care coordination may enhance adherence to guideline-based breast cancer treatment.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...